MRD Response-adapted Allo-HSCT for Adverse-risk AML
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.
- EligibilityCriteria: Inclusion Criteria:  Newly diagnosed AML; Categorized into adverse-risk group according to ELN 2022 criteria; 16-65 years of age at the time of diagnosis; achieving CR after 1 or 2 courses of induction chemotherapies;  4) ECOG PS score of 0 to 1 5) It needs consent from the patients or/and legal guardian, and signature on the Informed Consent.  Exclusion Criteria:  Newly diagnosed AML, but categorized into favorite- or intermediate-risk group according to ELN 2022 criteria; < 16 years, or older than 65 years at the time of diagnosis; Achieving CR after 3 or more courses of induction chemotherapies, or could not achieve CR after induction chemotherapies; ECOG PS score of 2 or more; Patients with other comorbidities or mental diseases that influence the life safety and compliance of patients as well as affect informed consent, enrollment in the research, follow-up visit or result interpretation. - HealthyVolunteers: No - Gender: All - MinimumAge: 16 Years - MaximumAge: 65 Years - StdAgeList: Child, Adult, Older Adult